A hepatitis B immunity test is a blood draw that measures antibodies to the hepatitis B surface antigen, known as anti-HBs. The key number is 10 mIU/mL: a level at or above that threshold is widely accepted as evidence of protection against the virus. But the meaning of a result, especially one that falls below that cutoff, is more nuanced than a simple pass/fail, and the circumstances that prompt the test matter for how you and your doctor should interpret it.
What the Test Measures
The standard hepatitis B immunity test is a quantitative blood assay that detects anti-HBs, the antibody your immune system produces in response to either vaccination or natural infection. When you get vaccinated, the vaccine introduces the hepatitis B surface antigen (a protein from the virus’s outer coat) so your body learns to recognize and fight it. The anti-HBs antibody is the measurable evidence that this training happened.
A result of 10 mIU/mL or higher is generally classified as “protective” or “immune.” Results above 100 mIU/mL are sometimes reported in a separate tier, which can cause confusion, but for clinical purposes the 10 mIU/mL line is what matters. Any immunocompetent person who completed a proper vaccination course and ever tested above 10 mIU/mL is considered immune, even if a later test shows a lower number.1Australian Family Physician. Hepatitis B serology
Depending on the clinical situation, the test may be ordered alongside other hepatitis B markers: hepatitis B surface antigen (HBsAg), which indicates active infection, and antibody to the hepatitis B core antigen (anti-HBc), which signals prior exposure to the virus itself. These additional markers help distinguish between someone who is immune from vaccination, someone who cleared a past infection, and someone who is currently infected.
Interpreting Common Result Patterns
Your results will typically fall into one of a few recognizable patterns. If you have anti-HBs above 10 mIU/mL with no HBsAg and no anti-HBc, that is straightforward vaccine-induced immunity. If you have anti-HBs along with anti-HBc but no HBsAg, you likely had a past infection that your body cleared. If HBsAg is positive and anti-HBs is negative, you have an active or chronic infection. And if everything comes back negative, you have no immunity and no infection, meaning vaccination is the next step.
One pattern trips people up: a positive anti-HBc result with no anti-HBs and no HBsAg. This “isolated anti-HBc” pattern is common enough that it has its own clinical literature. It can mean a few things: a remote past infection where anti-HBs has faded below detectable levels, a false positive on the anti-HBc test, or in some cases, an occult (hidden) hepatitis B infection where the virus persists at very low levels.2American Journal of Gastroenterology. Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody—A Review of New Issues The clinical significance of this pattern depends heavily on the person’s immune status and risk factors. In immunocompromised patients especially, isolated anti-HBc raises concern about potential viral reactivation if the immune system is further suppressed.3PubMed Central. Isolated Anti-HBc: Significance and Management
Low-level positive results also deserve caution. Older research found that low-level anti-HBs detected in isolation (without anti-HBc) persisted for a year in fewer than half the people tested, and only about a third of that group showed a boosted response to vaccination, suggesting many of those low-level results were nonspecific rather than evidence of true immunity.4PubMed Central. Epidemiological analysis of the significance of low-positive test results for antibody to hepatitis B surface and core antigens
How Long Vaccine-Induced Immunity Lasts
One of the most common reasons people get an immunity test years after vaccination is to find out whether they are still protected. The reassuring answer, backed by some of the longest follow-up studies available, is that protection persists for decades. A cohort study in Alaska tracked people for 41 years after their primary vaccine series. At that point, about a third still had circulating anti-HBs at or above 10 mIU/mL, and an additional 59% showed immune memory when challenged with a booster dose. The overall proportion with evidence of protection was 91% at 41 years, and only 1% of participants had any evidence of a breakthrough infection over the entire follow-up period. None of those breakthroughs became chronic hepatitis B.5PubMed Central. Long-term protection following a primary series of hepatitis B vaccine in Alaska Native children and adults
A related analysis at 35 years found that 86% of participants had either protective antibody levels or responded to a booster dose.6PubMed Central. Protection and antibody levels 35 years after primary series with hepatitis B vaccine and response to a booster dose And a 30-year study concluded that over 90% of participants showed evidence of protection and that routine booster doses are not needed.7PubMed. Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose
These are striking numbers. A vaccine you received as an infant or young adult still works decades later for the vast majority of people, even if your blood test now shows an anti-HBs level that has slipped below 10 mIU/mL.
Why Low Antibody Levels Do Not Necessarily Mean You Are Unprotected
This is the single most misunderstood result on a hepatitis B immunity test. You get tested, your anti-HBs comes back at 5 or 7 mIU/mL, and you assume your immunity has worn off. In many cases, that assumption is wrong. The 10 mIU/mL cutoff is a population-level marker, not a biological on-off switch. Immune memory, stored in long-lived T and B cells, can persist even when circulating antibody levels drop below that threshold.
Studies in people who lost measurable anti-HBs after vaccination found that they still had hepatitis B surface antigen-specific memory T and B cells. When given a booster, those T cells were able to trigger B cells into rapidly producing anti-HBs again.8PubMed. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination Follow-up research in adults tested two to three decades after their primary vaccination confirmed this: even with low circulating memory B-cell levels before a challenge dose, an increase in hepatitis B-specific memory B cells appeared within seven days of a booster, and specific CD4+ T-cell responses were detectable within that same window.9PubMed Central. Persistence of HBsAg‐specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults
Perhaps the most persuasive data come from children born to hepatitis B-infected mothers. A longitudinal study followed 395 vaccinated children and found that none became infected over roughly five years of follow-up, including 62 unboosted children whose anti-HBs had dropped below 10 mIU/mL. Given the close household contact these children had with their infected mothers, the researchers concluded that successfully vaccinated children remain immune even after antibody levels fall below the conventional protective line.10PubMed Central. Level of antibody to hepatitis B surface antigen declined below 10 mIU/ml is still protective
Who Actually Needs the Test
Not everyone needs a hepatitis B immunity test, and guidelines differ by country and context. The groups most commonly tested include:
- Healthcare workers: Post-vaccination testing is standard for anyone with occupational exposure to blood and body fluids. The goal is to confirm a protective response before a needlestick or other exposure occurs, rather than scrambling afterward. Research has shown that routinely confirming immunity status before any exposure is more cost-effective than managing each exposure event individually.11PubMed Central. Post-vaccination anti-HBs testing among healthcare workers: More economical than post-exposure management for Hepatitis B
- Infants born to HBsAg-positive mothers: These babies receive hepatitis B vaccine and hepatitis B immune globulin (HBIG) at birth. Post-vaccination testing confirms the immunoprophylaxis worked and that the infant was not infected despite the exposure. Current guidance recommends testing these infants between 9 and 15 months of age, which avoids detecting passive antibodies from the HBIG that was given at birth while still being early enough to catch late infections.12PubMed Central. Timing of post-vaccination tests in infants born to mothers with chronic hepatitis B virus infection
- People at ongoing risk: This includes sexual partners of hepatitis B carriers, people who inject drugs, dialysis patients, and others with continued exposure risk.
- Adults being screened at STI clinics: Modeling studies have found that adding one-time hepatitis B testing for adults seeking STI care is cost-saving overall, preventing cases of cirrhosis, liver cancer, and liver-related deaths while also identifying people who need vaccination.13PubMed Central. Cost-Effectiveness of Hepatitis B Testing and Vaccination of Adults Seeking Care for Sexually Transmitted Infections
For the general population with no particular risk factors who were vaccinated as children, routine post-vaccination immunity testing is not recommended. The evidence on long-term protection is strong enough that checking antibody levels “just in case” is not considered worthwhile.
What If You Are a Non-Responder
About 5 to 10% of healthy adults do not develop a protective anti-HBs level after a standard three-dose vaccine series. If your post-vaccination test comes back below 10 mIU/mL and you were never previously infected, you are classified as a non-responder. The risk is higher in people who are older, obese, smokers, immunocompromised, or on dialysis.
The standard first step is revaccination, often with a full repeat series. But the choice of vaccine matters. A trial comparing different revaccination strategies in healthy non-responders found that higher-dose and adjuvanted vaccine formulations produced significantly more responders than simply repeating the standard vaccine.14The Lancet Infectious Diseases. Comparative immunogenicity of three revaccination regimens in non-responders to primary hepatitis B vaccination A newer vaccine called Heplisav-B, which uses a different adjuvant, has shown promise for this group. In a small case series, 12 out of 13 prior non-responders achieved protective antibody levels after completing the Heplisav-B series.15Military Medicine. Heplisav-B in Prior Hepatitis B Vaccine Nonresponders: A Case Series
Dialysis patients are a particularly challenging group. Their immune systems are compromised by kidney failure, which blunts the vaccine response. A trial comparing two vaccines in dialysis patients found seroconversion rates of roughly 70-73%, far below the near-universal response seen in healthy adults.16PubMed. A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B-Vac, as compared to Engerix B, among vaccine naïve and vaccine non-responder dialysis patients For these patients, periodic antibody testing is more important than for the general population, and dialysis units have specific protocols around hepatitis B surveillance.
Accuracy of Different Testing Methods
Most hospital and clinic labs measure anti-HBs using either ELISA or chemiluminescence immunoassay (CLIA). These two methods agree well: one head-to-head comparison found 96.5% agreement when classifying results as protective and about 91% agreement when classifying them as non-protective. A small number of discordant results occurred near the 10 mIU/mL cutoff, where one method called a sample protective and the other did not.17PubMed Central. Comparing Assay Performance of ELISA and Chemiluminescence Immunoassay in Detecting Antibodies to Hepatitis B Surface Antigen If your result is right around the cutoff, keep in mind that a different lab platform might give a slightly different answer.
Rapid point-of-care tests exist for anti-HBs, and they are appealing for field settings and low-resource clinics. However, their sensitivity is disappointing compared to lab-based assays. A large French study found that one rapid anti-HBs test had a specificity of about 98% but a sensitivity of only 58%, meaning it missed a large share of people who were actually immune.18PubMed. Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France A subsequent evaluation of multiple rapid tests confirmed similar findings: sensitivity improved dramatically when antibody levels were above 100-150 mIU/L, reaching 90% or more in that range, but at lower titers the tests frequently returned false negatives.19PubMed. Performance of rapid diagnostic tests for the detection of anti-HBs in various patient populations In other words, a rapid test can confirm strong immunity fairly reliably, but it is not trustworthy for ruling out moderate or borderline immunity.
Pre-Vaccination Screening Versus Just Vaccinating
If you are an adult who is unsure whether you were ever vaccinated or previously infected, you might wonder whether it makes sense to test first or simply get vaccinated. In most situations, it is more cost-effective to just vaccinate. An economic analysis across multiple populations found that vaccinating without screening was less costly and at least equally effective as screening first in the vast majority of scenarios. Pre-vaccination testing only saved money when directed at groups with a very high probability of already being immune.20PubMed Central. An economic assessment of pre-vaccination screening for hepatitis A and B There is no harm in receiving the hepatitis B vaccine if you are already immune, so the practical advice for most adults is: if in doubt, get vaccinated.
Occult Hepatitis B and the Limits of Standard Testing
Standard serological tests look for surface antigen, surface antibody, and core antibody. These are excellent screening tools, but they have a blind spot. Occult hepatitis B infection (OBI) refers to a condition where the virus’s genetic material is present in the liver, but the surface antigen test comes back negative.21PubMed Central. Occult Hepatitis B Virus Infection: An Update The virus is replicating at very low levels, below the radar of standard blood tests.
Detecting OBI requires specialized DNA testing. The gold standard remains analysis of liver tissue, but since liver biopsies are obviously impractical for routine screening, most research relies on highly sensitive blood-based DNA assays.22Journal of Hepatology. Occult hepatitis B virus infection Even with blood testing, the detection rate depends on how sensitive the assay is. One study found that using the proper lower limit of detection yielded an OBI detection rate of about 4%, compared to only 1.5% when a less sensitive threshold was applied.23PubMed. Misuse of the Lower Limit of Detection in HBV DNA Testing and Anti-HBe Positive Status Will Significantly Impact the Diagnosis of Occult HBV Infection
OBI matters clinically in certain contexts: organ donation, blood transfusion safety, and immunosuppressive therapy, where reactivation of a hidden virus can cause serious liver disease. For the average person getting a routine immunity check, OBI is not something you need to worry about. But if you have an unexplained isolated anti-HBc pattern, or you are about to start potent immunosuppression, your doctor may order hepatitis B DNA testing to look deeper than the standard antibody panel can see.
Escape Mutants and Vaccine-Era Variants
Widespread vaccination has been one of the great public health successes in reducing hepatitis B globally, but it has also created selective pressure on the virus. Mutations in the surface antigen gene can produce variants that partially or fully escape recognition by the antibodies induced by vaccination.24PubMed Central. Hepatitis B surface antigen escape mutations: Indications for initiation of antiviral therapy revisited These escape mutants have been linked to cases of vaccine failure and to reinfection after liver transplantation despite the patient receiving hepatitis B immune globulin.25PubMed Central. Impaired virion secretion by hepatitis B virus immune escape mutants and its rescue by wild-type envelope proteins or a second-site mutation
From a practical standpoint, escape mutants remain uncommon and current vaccines are still highly effective. But the phenomenon means that a positive anti-HBs result, while strongly reassuring, is not an absolute guarantee against every strain of the virus. It also means that surveillance of circulating hepatitis B variants is an ongoing concern for public health authorities, and future vaccines may need to be updated to keep pace with viral evolution, in much the same way influenza vaccines are reformulated.
Dialysis Patients and Other Immunocompromised Groups
If your immune system is weakened by kidney disease, HIV, chemotherapy, or immunosuppressive drugs, the usual rules about hepatitis B immunity testing change in important ways. You are less likely to respond to vaccination in the first place, and even if you do mount a response, your antibody levels may decline faster. For dialysis patients in particular, periodic retesting of anti-HBs levels is standard practice, because immunity can wane to the point where a booster is genuinely needed.
There is an additional wrinkle for dialysis units. Even patients who test positive for anti-HBs and appear immune can, in rare cases, harbor chronic inactive hepatitis B infection. One case highlighted by the American Society of Nephrology noted that standard guidelines did not recommend rechecking surface antigen in dialysis patients with established immunity, but transient viremia in such patients could theoretically allow transmission during dialysis sessions. The authors argued that adding surface antigen testing to routine surveillance in dialysis units could reduce that risk.26American Society of Nephrology. Hepatitis B Prevention in Dialysis – Needs Reconsideration This is a niche scenario, but it underscores how the interpretation of immunity test results depends on the clinical setting.
Testing Infants Born to Infected Mothers
The timing of post-vaccination testing in newborns exposed to hepatitis B at birth is a question with real practical stakes. Test too early, and you might detect residual antibodies from the HBIG shot given at birth, falsely inflating the result. Test too late, and you miss the window to intervene if the infant did not mount its own immune response or, worse, became infected.
Most guidance settles on testing between 9 and 15 months of age for infants who received the standard immunoprophylaxis at birth.27PubMed Central. Timing of post-vaccination tests in infants born to mothers with chronic hepatitis B virus infection Some researchers have proposed that testing as early as 7 months (one month after the final vaccine dose in a 0-1-6 schedule) could identify non-responders sooner, allowing earlier revaccination.28PubMed Central. The optimal interval for post-vaccination serological test in infants born to mothers with positive hepatitis B surface antigen The trade-off is a slightly higher chance of a false signal from lingering passive antibodies. For parents navigating this, the practical takeaway is to follow your pediatrician’s guidance on when to test, and to make sure the test actually gets done. Missed or delayed post-vaccination testing is a real gap in hepatitis B prevention programs for at-risk infants.